| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Sinovac Biotech Ltd.
13D/A
SVA · P8696W104
|
6.3% |
3/19/2025
Event 3/17/2025
|
||||
| Vivo Capital VIII, LLC | 1.9% | |||||
| Vivo Capital IX, LLC | 6.3% | |||||
| Schedule 13G · 3 securities · passive | ||||||
|
IO Biotech, Inc.
13G/A
IOBTQ · 449778109
|
4.6% |
11/14/2025
Event 9/30/2025
|
||||
| Vivo Capital IX, LLC | 0% | |||||
| Vivo Capital Fund IX, L.P. | 0% | |||||
| Vivo Opportunity, LLC | 4.6% | |||||
| Vivo Opportunity Fund Holdings, L.P. | 4.6% | |||||
|
Instil Bio, Inc.
13G/A
TIL · 45783C200
|
4.5% |
8/12/2025
Event 6/30/2025
|
||||
| Vivo Capital IX, LLC | 4.5% | |||||
| Vivo Capital Fund IX, L.P. | 4.5% | |||||
|
Sera Prognostics, Inc.
13G/A
SERA · 81749D107
|
4.5% |
5/15/2025
Event 3/31/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.